{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T16:26:55Z","timestamp":1747153615334,"version":"3.40.5"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T00:00:00Z","timestamp":1582675200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T00:00:00Z","timestamp":1582675200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s00428-020-02778-9","type":"journal-article","created":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T21:03:44Z","timestamp":1582751024000},"page":"429-436","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chemotherapy-associated foam cell aggregates as a prognostic factor in patients with pelvic high-grade serous carcinoma receiving neo-adjuvant chemotherapy"],"prefix":"10.1007","volume":"477","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6963-3824","authenticated-orcid":false,"given":"Naoki","family":"Kojima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikumi","family":"Kuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Ushigusa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyasu","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7569-7813","authenticated-orcid":false,"given":"Hiroshi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,26]]},"reference":[{"key":"2778_CR1","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1056\/NEJMoa0908806","volume":"363","author":"I Vergote","year":"2010","unstructured":"Vergote I, Trop\u00e9 CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg M, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS, European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group, NCIC Clinical Trials Group (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363:943\u2013953","journal-title":"N Engl J Med"},{"key":"2778_CR2","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","volume":"386","author":"S Kehoe","year":"2015","unstructured":"Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, Luesley D, Perren T, Bannoo S, Mascarenhas M, Dobbs S, Essapen S, Twigg J, Herod J, McCluggage G, Parmar M, Swart AM (2015) Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 386:249\u2013257","journal-title":"Lancet"},{"key":"2778_CR3","doi-asserted-by":"crossref","unstructured":"Vergote I, Coens C, Nankivell M et al (2018) Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncol 0:1\u20138","DOI":"10.1016\/S1470-2045(18)30566-7"},{"key":"2778_CR4","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1200\/JCO.2014.60.5212","volume":"33","author":"S B\u00f6hm","year":"2015","unstructured":"B\u00f6hm S, Faruqi A, Said I, Lockley M, Brockbank E, Jeyarajah A, Fitzpatrick A, Ennis D, Dowe T, Santos JL, Cook LS, Tinker AV, le ND, Gilks CB, Singh N (2015) Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma. J Clin Oncol 33:2457\u20132463","journal-title":"J Clin Oncol"},{"key":"2778_CR5","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/modpathol.2015.77","volume":"28","author":"W Glenn Mccluggage","year":"2015","unstructured":"Glenn Mccluggage W, Judge MJ, Clarke BA et al (2015) Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Mod Pathol 28:1101\u20131122","journal-title":"Mod Pathol"},{"key":"2778_CR6","unstructured":"College of American Pathologists (2018) Protocol for the examination of specimens from patients with primary tumours of the ovary, fallopian tube, or peritoneum. https:\/\/www.cap.org\/protocols-and-guidelines\/cancer-reporting-tools\/cancer-protocol-templates."},{"key":"2778_CR7","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1097\/IGC.0000000000000945","volume":"27","author":"E Coghlan","year":"2017","unstructured":"Coghlan E, Meniawy TM, Munro A, Bulsara M, Stewart CJ, Tan A, Koay MHE, MaGee D, Codde J, Tan J, Salfinger SG, Mohan GR, Leung Y, Nichols CB, Cohen PA (2017) Prognostic role of histological tumour regression in patients receiving neoadjuvant chemotherapy for high-grade serous tubo-ovarian carcinoma. Int J Gynecol Cancer 27:708\u2013713","journal-title":"Int J Gynecol Cancer"},{"key":"2778_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3802\/jgo.2017.28.e1","volume":"28","author":"JY Lee","year":"2017","unstructured":"Lee JY, Chung YS, Na K et al (2017) External validation of chemotherapy response score system for histopathological assessment of tumour regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma. J Gynecol Oncol 28:1\u20139","journal-title":"J Gynecol Oncol"},{"key":"2778_CR9","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/his.13399","volume":"72","author":"P Singh","year":"2018","unstructured":"Singh P, Kaushal V, Rai B, Rajwanshi A, Gupta N, Dey P, Garg R, Rohilla M, Suri V, Ghoshal S, Srinivasan R (2018) The chemotherapy response score is a useful histological predictor of prognosis in high-grade serous carcinoma. Histopathology 72:619\u2013625","journal-title":"Histopathology"},{"key":"2778_CR10","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.ygyno.2018.08.042","volume":"151","author":"S Rajkumar","year":"2018","unstructured":"Rajkumar S, Polson A, Nath R, Lane G, Sayasneh A, Jakes A, Begum S, Mehra G (2018) Prognostic implications of histological tumour regression (B\u00f6hm\u2019s score) in patients receiving neoadjuvant chemotherapy for high grade serous tubal & ovarian carcinoma. Gynecol Oncol 151:264\u2013268","journal-title":"Gynecol Oncol"},{"key":"2778_CR11","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/PGP.0000000000000513","volume":"38","author":"HM Ditzel","year":"2019","unstructured":"Ditzel HM, Strickland KC, Meserve EE, Stover E, Konstantinopoulos PA, Matulonis UA, Muto MG, Liu JF, Feltmate C, Horowitz N, Berkowitz RS, Gupta M, Hecht JL, Lin DI, Jochumsen KM, Welch WR, Hirsch MS, Quade BJ, Lee KR, Crum CP, Mutter GL, Nucci MR, Howitt BE (2019) Assessment of a Chemotherapy Response Score (CRS) system for tubo-ovarian high-grade serous carcinoma (HGSC). Int J Gynecol Pathol 38:230\u2013240","journal-title":"Int J Gynecol Pathol"},{"key":"2778_CR12","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.ygyno.2019.04.679","volume":"154","author":"PA Cohen","year":"2019","unstructured":"Cohen PA, Powell A, B\u00f6hm S et al (2019) Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: a systematic review and meta-analysis of individual patient data. Gynecol Oncol 154:441\u2013448","journal-title":"Gynecol Oncol"},{"key":"2778_CR13","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.humpath.2006.12.008","volume":"38","author":"S Sassen","year":"2007","unstructured":"Sassen S, Schmalfeldt B, Avril N et al (2007) Histopathologic assessment of tumour regression after neoadjuvant chemotherapy in advanced-stage ovarian cancer. Hum Pathol 38:926\u2013934","journal-title":"Hum Pathol"},{"key":"2778_CR14","unstructured":"Genetic Pathology Evaluation Centre (2019) Chemotherapy Response Score (CRS): training web site for CRS system. http:\/\/www.gpecimage.ubc.ca\/aperio\/images\/crs\/."},{"key":"2778_CR15","doi-asserted-by":"publisher","first-page":"632.e1","DOI":"10.1016\/j.ajog.2014.06.034","volume":"211","author":"M Petrillo","year":"2014","unstructured":"Petrillo M, Zannoni GF, Tortorella L et al (2014) Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. Am J Obstet Gynecol 211:632.e1\u2013632.e8","journal-title":"Am J Obstet Gynecol"},{"key":"2778_CR16","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant 48:452\u2013458","journal-title":"Bone Marrow Transplant"},{"key":"2778_CR17","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1097\/PGP.0000000000000307","volume":"36","author":"I Said","year":"2017","unstructured":"Said I, B\u00f6hm S, Beasley J, Ellery P, Faruqi AZ, Ganesan R, Hirschowitz L, Jeetle S, Leen SL, McCluggage W, McDermott J, Merard R, Millner TO, Trevisan G, Vella J, Gilks CB, Singh N (2017) The chemotherapy response score (CRS): Interobserver reproducibility in a simple and prognostically relevant system for reporting the histologic response to neoadjuvant chemotherapy in tuboovarian high-grade serous carcinoma. Int J Gynecol Pathol 36:172\u2013179","journal-title":"Int J Gynecol Pathol"},{"key":"2778_CR18","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1084\/jem.20101157","volume":"207","author":"KS Ravichandran","year":"2010","unstructured":"Ravichandran KS (2010) Find-me and eat-me signals in apoptotic cell clearance: progress and conundrums. J Exp Med 207:1807\u20131817","journal-title":"J Exp Med"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-020-02778-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00428-020-02778-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-020-02778-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T00:09:42Z","timestamp":1614211782000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00428-020-02778-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,26]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["2778"],"URL":"https:\/\/doi.org\/10.1007\/s00428-020-02778-9","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"type":"print","value":"0945-6317"},{"type":"electronic","value":"1432-2307"}],"subject":[],"published":{"date-parts":[[2020,2,26]]},"assertion":[{"value":"25 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The present study has been approved by the institutional review board of the National Cancer Center Japan and was conducted in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}